CCO Treatment Updates
HBV Treatment: What to Start?
Module
HBV Treatment: What to Start?
|
|
|
Robert G. Gish, MD, describes the latest data and reviews the most recent guidelines on the optimal selection of first-line therapy for patients with chronic hepatitis B infection.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the latest clinical data and best practices regarding treatment strategies for treatment-naive patients with chronic hepatitis B infection
- Discuss differences between FDA-approved treatments for chronic hepatitis B infection
- Discuss the impact of HBeAg status on selection of most appropriate therapy for patients with chronic hepatitis B infection
Abstract
|
HBV Treatment: What to Start?
 |
|
Download slide highlights from the CME-certified module on initial HBV therapies for self study and use in your own presentations.
Format: Microsoft PowerPoint (.ppt) |
File size: 1.40 MB
| Date posted: 5/29/2009
|
Interactive Case Challenges
Managing Initial Treatment for an Asian American Patient With HBeAg-Positive Chronic Hepatitis B
|
|
|
Learn about frontline regimen selection and on-treatment management of an HBeAg-positive patient and apply this learning with Albert D. Min, MD, in this Interactive Case Challenge.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe clinical considerations relevant to the choice of an optimal initial HBV treatment strategy for HBeAg-positive patients
- Explain the latest clinical data and best practices regarding treatment strategies for treatment-naive HBeAg-positive patients with chronic hepatitis B
- Cite differences in on-treatment monitoring and managing of HBeAg-positive patients with chronic hepatitis B
|
Management of Initial HBV Therapy for an HBeAg-Negative Patient
- Calvin Q. Pan, MD, FACP, FACG
|
|
|
Attempt this Interactive Case Challenge and learn strategies for frontline regimen selection and on-treatment management of patients with HBeAg-negative chronic HBV infection with Calvin Q. Pan, MD, FACP, FACG.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe clinical considerations relevant to the choice of an optimal initial HBV treatment strategy for HBeAg-negative patients
- Compare and contrast the latest clinical data and best practices regarding treatment strategies for treatment-naive patients with HBeAg-negative chronic HBV infection
- Synthesize and apply differences in initial management strategies for patients with HBeAg-negative chronic HBV infection
|
Disclaimer:
The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
|
|